Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information


King of Prussia, USA
1018 West 8th Avenue
Suite A
King of Prussia, PA, 19406


President and CEO
Vice President and Head, Chemistry
Board Director
Board of Directors
Senior Vice President and Head, Research
Chief Business Officer


Series A, 3/2008
HealthCare Ventures
New Enterprise Associates
Polaris Partners
Alta Partners
Series B, 7/2010
New Enterprise Associates
Polaris Partners
Alta Partners
HealthCare Ventures
Grant, 8/2011
Series C, 5/2013
Forest Laboratories



Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines.

We have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.

G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena’s biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.

Recent Milestones



Trevena screenshot
Above: Homepage
Uploaded: 6/18/09


  1. Trevena, Inc. Announces $24 Million Series A Financing ( [edit]
  2. Trevena, Inc.: Series B $35M ( [edit]
  3. Trevena Jumps Into Antidepressant Market Through $10M NIH Grant ( [edit]
  4. Trevena Raises $60M Series C, Strikes $430M Option Deal With Forest L ( [edit]
Edit This Page
Last Edited 12/4/13

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy